Global NASH Council Chair Zobair Younossi joins the Surfers to discuss his recent review article on MASLD epidemiology and what stakeholders can do to help stem the tsunami of new patients.
HistoIndex Chief Scientific Officer Dean Tai joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss how advances in MASLD artificial intelligence will spur knowledge, insight and innovation in drug development and NITs.
Hepatology researcher and Key Opinion Leader Naim Alkhouri joins Louise Campbell and Roger Green to discuss advances in drug development and NITs and to share thoughts about efficacious use of clinical care pathways.
Profs. Laurent Castera and Scott Friedman join Louise Campbell and Roger Green to discuss highlights of the recent TLM2023 conference.
In this episode From the Vault, Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from the 2021 Paris NASH meeting, an event with exciting scientific messages and insights. This episode has played out to be by far the most downloaded segment in the podcast’s history!
In this final conversation, the Surfers are joined by Veronica Miller to discuss the recent FDA workshop for NIT development. Veronica discusses her unique impressions on the workshop and steers the group to consider the question of “why are we validating a surrogate with a surrogate?”
In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. This discussion largely focuses on ideas around distinguishing the difference between NITs to qualify patients for trials versus to evaluate efficacy of drugs.
In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. Laurent focuses on why this workshop is important within its context of being hosted by the FDA and what that means for researchers and stakeholders across the globe. He also dives into the complexities of hepatocellular ballooning and its potential impact on patients receiving NASH pharmacotherapy.
In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. The group discusses loss aversion, screen fail rates, the future of FDA decision making and more.
In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. Naim expands on ideas around an NIT-based alternative path to conditional approval as well as provides a general survey of how the workshop played out as he served as an expert panelist in Tuesday’s penultimate session.
